ReviewCurrent allergy and asthma reports2022
Multisystem Inflammatory Syndrome in Children (MIS-C).
Review in Current allergy and asthma reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 155 citations in OpenAlex.
- Effect of COVID-19 on Retinal and Choroidal Microvasculature in the Pediatric Population: A Literature Review.Medicina (Kaunas, Lithuania) · 2026Review
- Comparative Analysis of Routine Blood Laboratory Tests in Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease Among White and Black Children.Pediatric cardiology · 2026Article
- Severe, primary, and incidental COVID-19 in hospitalised children, South Africa: 2020-2023.Journal of global health · 2026Article
- Differentiating Multisystem Inflammatory Syndrome in Children (MIS-C) from Acute COVID-19 Using Biomarkers: Toward a Practical Clinical Scoring Model.Biomedicines · 2026Article
- Resurgence and clinical evolution of influenza A in Chinese children: shifting epidemiology and serological dynamics across pre-, intra-, and post-pandemic eras (2019-2023).BMC infectious diseases · 2026Article
- MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026Review
- Association of blood group B and of rare variants affecting immune system with multisystem inflammatory syndrome in children in an Italian cohort.Frontiers in immunology · 2026Article
- Case Report: MIS-C precipitating DKA and renal failure in a morbidly obese male with type 2 diabetes mellitus.Frontiers in pediatrics · 2026Article
- Rare disease mimicking multisystem inflammatory syndrome in children.BMC pediatrics · 2025Article
- Reduced aerobic capacity in children with multisystem inflammatory syndrome in children (MIS-C) after PICU admission: a retrospective cohort study, 2020-2022.BMC pediatrics · 2025Article
- Cardiac Manifestations and Persistent Myocardial Dysfunction in Multisystem Inflammatory Syndrome in Children: Insights from Conventional and Strain Echocardiography.Children (Basel, Switzerland) · 2025Article
- Intra-Host Evolution of SARS-CoV-2 During Persistent Infection of Pediatric COVID-19 Patients.Viruses · 2025Article
- Detecting heart failure in severe asthma patients using speckle tracking echocardiography.Critical care (London, England) · 2025Article
- Review
- Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection.Stem cells translational medicine · 2025Article
- Vitamin D Imbalance and Hydro-Electrolyte Disturbances in Hospitalized Children: A Comparation Between Post-COVID-19 Status and SARS-CoV-2/EBV Coinfection.Biomedicines · 2025Article
- Prognostic significance of asymmetric dimethyl arginine level in pediatric patients with COVID-19 infection and MIS-C.European journal of pediatrics · 2025Observational
- Phenotypic Classification of Multisystem Inflammatory Syndrome in Children Using Latent Class Analysis.JAMA network open · 2025Article
- Pediatric Gastrointestinal Disorders in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With COVID-19: A Case Series.Case reports in pediatrics · 2025Article
- Progress on diagnosis and treatment of multisystem inflammatory syndrome in children.Frontiers in immunology · 2025Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has developed into a pandemic. A unique challenge of this pandemic has been the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare post-infectious hyperinflammatory disorder associated with SARS-CoV-2. This syndrome is characterized by overwhelming systemic inflammation, fever, hypotension, and cardiac dysfunction. This disorder may also have features overlapping with Kawasaki disease (KD), macrophage activation syndrome (MAS), and toxic shock syndrome (TSS). The goal of this review is to outline the presenting features, presumed immunopathogenesis, management, and outcomes of patients with MIS-C. RECENT
findingsPatients with MIS-C present with characteristics that fall within a wide clinical spectrum. Main features include fever, gastrointestinal symptoms such as abdominal pain and diarrhea, and cardiac complications such as myocarditis and coronary artery aneurysms, although various other features have been reported. Younger children may present with features of Kawasaki-like disease, and older children are often admitted to the intensive care unit with cardiogenic shock. Current treatment guidelines recommend intravenous immunoglobulins (IVIG) and glucocorticoids, with utilization of biologics in refractory cases. Fortunately, the majority of patients recover, with resolution of the systemic inflammation and cardiac abnormalities. Mortality from MIS-C is rare. This review provides an overview of the presenting features, proposed pathogenesis, suggested therapies, and outcomes of MIS-C. Clinicians must have a high clinical suspicion for this disorder in children who have had recent COVID-19 infection or exposure and present with a significant inflammatory response. Understanding of this disorder continues to evolve, and prompt diagnosis and treatment allow for the best possible outcome for patients with MIS-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.